Vaccine stocks plummet after RFK Jr. nominated as HHS secretary

We support our Publishers and Content Creators. You can view this story on their website by CLICKING HERE.

Pharmaceutical stocks are in free fall following President Donald Trump’s nomination of Robert F. Kennedy Jr. as secretary of Health and Human Services (HHS). Shares of Moderna (-30.6%), Novavax (-42.7%), and BioNTech (-11.9%) dropped sharply in premarket trading after the announcement, reflecting concerns over a potential shift in U.S. health policy under Kennedy’s leadership.

The downward spiral continued into European markets, where shares of vaccine producers like Sanofi and GSK also saw losses. The dramatic plunge in stock prices is the latest indicator of the uncertainty sweeping through the biotechnology sector following RFK Jr.’s nomination.

Stock market will falter if revolutionary changes are made to American medicine and food supply

If RFK Jr. is approved by Congress for the new role, he will oversee the hopelessly corrupt Centers for Disease Control (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH) and a slew of other agencies.

Kennedy, a long-time advocate for children’s health and environmental issues, has been one of the most vocal critics of vaccine policies in the U.S. He has publicly questioned the safety of vaccines and criticized the influence of pharmaceutical companies on public health, particularly the approval processes overseen by the Food and Drug Administration (FDA) and the propaganda underpinning the Centers for Disease Control’s (CDC) childhood vaccine schedule. He is perhaps best known for founding the nonprofit Children’s Health Defense, which analyzes medical and scientific literature and publishes compelling articles on the real health issues facing American families.

For years, Kennedy has represented individuals harmed by vaccines and has met directly with families in the autism community, who watched their kid decline following routine vaccinations. He has expressed concerns about the safety of vaccines, particularly the number of vaccinations given to young children, and has called for greater oversight of the vaccine approval process.

Trump’s embrace of Kennedy is more than an apology for unleashing Operation Warp Speed on Americans in 2020; it should be considered an act of contrition. Trump has embraced Kennedy’s stance, calling him a “health reformer” who will help reshape the nation’s health policies. During his victory speech on November 5, Trump stated, “He’s going to help make America healthy again. For too long, Americans have been crushed by the industrial food complex and drug companies.”

However, Wall Street analysts are sounding alarms over the potential fallout from Kennedy’s nomination. If RFK Jr. does anything significant reforming vaccine policies in the US, the stock market could crash in significant ways.

Goldman Sachs analyst Martin Ehigiator described Kennedy’s nomination as a “-3 standard deviation” event, meaning it has triggered an outsized market reaction. According to Ehigiator, the healthcare and pharmaceutical sectors are now in the spotlight due to Kennedy’s nomination. His skepticism toward vaccines, particularly mRNA technology, has been well-documented, with Kennedy warning that “something is wrong with that whole system.”

Deutsche Bank’s Emmanuel Papadakis also weighed in on the Kennedy nomination, downgrading shares of GSK to a “Hold” due to Kennedy’s known opposition to vaccine programs. “We consider vaccines to be amongst the greatest scientific achievements to impact public health,” Papadakis said. “Unfortunately, this view is not shared by the nominee.”

JPMorgan analyst Chris Schott expressed his concerns about RFK Jr., stating that “it’s difficult to evaluate the exact impact Kennedy would have on the biopharma industry at this point,” but added that his history of challenging the vaccine industry was likely contributing to the current market pressure.

CNN medical correspondent Dr. Sanjay Gupta opposes Kennedy’s mission. “I can’t think of any single individual who would be more damaging to public health than RFK.” Gupta warned, claiming that Kennedy’s stance on vaccines will erode public confidence in science and medicine – as if Big Pharma hasn’t already done that.

As the experts cry about losing control over the population on the issue of vaccination, the public is beginning to learn that the vaccine industry is not holding public health together at all. The vaccine industry is merely propping up the stock market and lining the pockets of billionaires, as they exploit children for their own gain.

Reforming CDC, FDA will require exorcism

If confirmed as HHS Secretary, Kennedy will be in charge of some 80,000 federal employees, most of whom are entrenched in agency capture, and beholden to their own propaganda and pride. Making major changes throughout HHS will require a major confrontation of evil. Data alone, which Kennedy already has on his side, will not break the strongholds. Kennedy will need to surround himself with God-fearing people who have faced corruption by leaning on the power of Almighty God through difficult times. Kennedy will need people who can discern and pray in the Spirit – people who have dealt with demonic possession and broken curses.

These federal agencies not only conceal pertinent information regarding health, but they also manipulate data and craft deceptive narratives that harm the public. Worse, these agencies refuse to acknowledge the damage they have done, implementing and affirming controversial medical experiments that have have maimed children for life and resulted in a modern day vaccine holocaust among the population.

If the stock market must fall as these curses are broken, then so be it.

Sources include: